WHO Grade Loses Its Prognostic Value in Molecularly Defined Diffuse Lower-Grade Gliomas

被引:23
作者
Carstam, Louise [1 ,2 ]
Corell, Alba [2 ]
Smits, Anja [2 ,3 ]
Denes, Anna [2 ]
Barcheus, Hanna [2 ]
Modin, Klara [2 ]
Sjogren, Helene [4 ]
Ferreyra Vega, Sandra [2 ,5 ]
Bontell, Thomas Olsson [2 ,6 ]
Caren, Helena [5 ]
Jakola, Asgeir Store [1 ,2 ,7 ]
机构
[1] Sahlgrens Univ Hosp, Dept Neurosurg, Gothenburg, Sweden
[2] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Gothenburg, Sweden
[3] Sahlgrens Univ Hosp, Dept Neurol, Gothenburg, Sweden
[4] Sahlgrens Univ Hosp, Clin Genet & Genom, Gothenburg, Sweden
[5] Univ Gothenburg, Sahlgrenska Acad, Sahlgrenska Ctr Canc Res, Dept Lab Med,Inst Biomed, Gothenburg, Sweden
[6] Sahlgrens Univ Hosp, Dept Clin Pathol & Cytol, Gothenburg, Sweden
[7] St Olavs Univ Hosp, Dept Neurosurg, Trondheim, Norway
来源
FRONTIERS IN ONCOLOGY | 2022年 / 11卷
关键词
lower-grade glioma; prognostic factors; WHO grade; IDH-mut; CDKN2A; B deletion; astrocytoma; oligodendroglioma; extent of resection; CENTRAL-NERVOUS-SYSTEM; GROSS-TOTAL RESECTION; COPY NUMBER ANALYSIS; IDH; SURVIVAL; CLASSIFICATION; ASTROCYTOMA; MUTATION; IMPACT; 1P/19Q;
D O I
10.3389/fonc.2021.803975
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundWhile molecular insights to diffuse lower-grade glioma (dLGG) have improved the basis for prognostication, most established clinical prognostic factors come from the pre-molecular era. For instance, WHO grade as a predictor for survival in dLGG with isocitrate dehydrogenase (IDH) mutation has recently been questioned. We studied the prognostic role of WHO grade in molecularly defined subgroups and evaluated earlier used prognostic factors in the current molecular setting. Material and MethodsA total of 253 adults with morphological dLGG, consecutively included between 2007 and 2018, were assessed. IDH mutations, codeletion of chromosomal arms 1p/19q, and cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) deletions were analyzed. ResultsThere was no survival benefit for patients with WHO grade 2 over grade 3 IDH-mut dLGG after exclusion of tumors with known CDKN2A/B homozygous deletion (n=157) (log-rank p=0.97). This was true also after stratification for oncological postoperative treatment and when astrocytomas and oligodendrogliomas were analyzed separately. In IDH-mut astrocytomas, residual tumor volume after surgery was an independent prognostic factor for survival (HR 1.02; 95% CI 1.01-1.03; p=0.003), but not in oligodendrogliomas (HR 1.02; 95% CI 1.00-1.03; p=0.15). Preoperative tumor size was an independent predictor in both astrocytomas (HR 1.03; 95% CI 1.00-1.05; p=0.02) and oligodendrogliomas (HR 1.05; 95% CI 1.01-1.09; p=0.01). Age was not a significant prognostic factor in multivariable analyses (astrocytomas p=0.64, oligodendrogliomas p=0.08). ConclusionOur findings suggest that WHO grade is not a robust prognostic factor in molecularly well-defined dLGG. Preoperative tumor size remained a prognostic factor in both IDH-mut astrocytomas and oligodendrogliomas in our cohort, whereas residual tumor volume predicted prognosis in IDH-mut astrocytomas only. The age cutoffs for determining high risk in patients with IDH-mut dLGG from the pre-molecular era are not supported by our results.
引用
收藏
页数:11
相关论文
共 48 条
  • [1] Prognostic relevance of genetic alterations in diffuse lower-grade gliomas
    Aoki, Kosuke
    Nakamura, Hideo
    Suzuki, Hiromichi
    Matsuo, Keitaro
    Kataoka, Keisuke
    Shimamura, Teppei
    Motomura, Kazuya
    Ohka, Fumiharu
    Shiina, Satoshi
    Yamamoto, Takashi
    Nagata, Yasunobu
    Yoshizato, Tetsuichi
    Mizoguchi, Masahiro
    Abe, Tatsuya
    Momii, Yasutomo
    Muragaki, Yoshihiro
    Watanabe, Reiko
    Ito, Ichiro
    Sanada, Masashi
    Yajima, Hironori
    Morita, Naoya
    Takeuchi, Ichiro
    Miyano, Satoru
    Wakabayashi, Toshihiko
    Ogawa, Seishi
    Natsume, Atsushi
    [J]. NEURO-ONCOLOGY, 2018, 20 (01) : 66 - 77
  • [2] CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas
    Appay, Romain
    Dehais, Caroline
    Maurage, Claude-Alain
    Alentorn, Agusti
    Carpentier, Catherine
    Colin, Carole
    Ducray, Francois
    Escande, Fabienne
    Idbaih, Ahmed
    Kamoun, Aurelie
    Marie, Yannick
    Mokhtari, Karima
    Tabouret, Emeline
    Trabelsi, Nesrine
    Uro-Coste, Emmanuelle
    Delattre, Jean-Yves
    Figarella-Branger, Dominique
    Desenclos, C.
    Sevestre, H.
    Menei, P.
    Rousseau, A.
    Cruel, T.
    Lopez, S.
    Mihai, M-I.
    Petit, A.
    Adam, C.
    Parker, F.
    Dam-Hieu, P.
    Quintin-Roue, I.
    Eimer, S.
    Loiseau, H.
    Bekaert, L.
    Chapon, F.
    Ricard, D.
    Godfraind, C.
    Khallil, T.
    Cazals-Hatem, D.
    Faillot, T.
    Gaultier, C.
    Tortel, M. C.
    Carpiuc, I.
    Richard, P.
    Lahiani, W.
    Aubriot-Lorton, H.
    Ghiringhelli, F.
    Maurage, C. A.
    Ramirez, C.
    Gueye, E. M.
    Labrousse, F.
    Chinot, O.
    [J]. NEURO-ONCOLOGY, 2019, 21 (12) : 1519 - 1528
  • [3] cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas
    Brat, Daniel J.
    Aldape, Kenneth
    Colman, Howard
    Figrarella-Branger, Dominique
    Fuller, Gregory N.
    Giannini, Caterina
    Holland, Eric C.
    Jenkins, Robert B.
    Kleinschmidt-DeMasters, Bette
    Komori, Takashi
    Kros, Johan M.
    Louis, David N.
    McLean, Catriona
    Perry, Arie
    Reifenberger, Guido
    Sarkar, Chitra
    Stupp, Roger
    van den Bent, Martin J.
    von Deimling, Andreas
    Weller, Michael
    [J]. ACTA NEUROPATHOLOGICA, 2020, 139 (03) : 603 - 608
  • [4] Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
    Brat, Daniel J.
    Verhaak, Roel G. W.
    Al-dape, Kenneth D.
    Yung, W. K. Alfred
    Salama, Sofie R.
    Cooper, Lee A. D.
    Rheinbay, Esther
    Miller, C. Ryan
    Vitucci, Mark
    Morozova, Olena
    Robertson, A. Gordon
    Noushmehr, Houtan
    Laird, Peter W.
    Cherniack, Andrew D.
    Akbani, Rehan
    Huse, Jason T.
    Ciriello, Giovanni
    Poisson, Laila M.
    Barnholtz-Sloan, Jill S.
    Berger, Mitchel S.
    Brennan, Cameron
    Colen, Rivka R.
    Colman, Howard
    Flanders, Adam E.
    Giannini, Caterina
    Grifford, Mia
    Iavarone, Antonio
    Jain, Rajan
    Joseph, Isaac
    Kim, Jaegil
    Kasaian, Katayoon
    Mikkelsen, Tom
    Murray, Bradley A.
    O'Neill, Brian Patrick
    Pachter, Lior
    Parsons, Donald W.
    Sougnez, Carrie
    Sulman, Erik P.
    Vandenberg, Scott R.
    Van Meir, Erwin G.
    von Deimling, Andreas
    Zhang, Hailei
    Crain, Daniel
    Lau, Kevin
    Mallery, David
    Morris, Scott
    Paulauskis, Joseph
    Penny, Robert
    Shelton, Troy
    Sherman, Mark
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26) : 2481 - 2498
  • [5] Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
    Buckner, Jan C.
    Shaw, Edward G.
    Pugh, Stephanie L.
    Chakravarti, Arnab
    Gilbert, Mark R.
    Barger, Geoffrey R.
    Coons, Stephen
    Ricci, Peter
    Bullard, Dennis
    Brown, Paul D.
    Stelzer, Keith
    Brachman, David
    Suh, John H.
    Schultz, Christopher J.
    Bahary, Jean-Paul
    Fisher, Barbara J.
    Kim, Harold
    Murtha, Albert D.
    Bell, Erica H.
    Won, Minhee
    Mehta, Minesh P.
    Curran, Walter J., Jr.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (14) : 1344 - 1355
  • [6] Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases
    Capelle, Laurent
    Fontaine, Denys
    Mandonnet, Emmanuel
    Taillandier, Luc
    Golmard, Jean Louis
    Bauchet, Luc
    Pallud, Johan
    Peruzzi, Philippe
    Baron, Marie Helene
    Kujas, Michele
    Guyotat, Jacques
    Guillevin, Remi
    Frenay, Marc
    Taillibert, Sophie
    Colin, Philippe
    Rigau, Valerie
    Vandenbos, Fanny
    Pinelli, Catherine
    Duffau, Hugues
    [J]. JOURNAL OF NEUROSURGERY, 2013, 118 (06) : 1157 - 1168
  • [7] Preoperative prognostic classification system for hemispheric low-grade gliomas in adults
    Chang, Edward F.
    Smith, Justin S.
    Chang, Susan M.
    Lamborn, Kathleen R.
    Prados, Michael D.
    Butowski, Nicholas
    Barbaro, Nicholas M.
    Parsa, Andrew T.
    Berger, Mitchel S.
    McDermott, Michael M.
    [J]. JOURNAL OF NEUROSURGERY, 2008, 109 (05) : 817 - 824
  • [8] Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas
    Cimino, Patrick J.
    Holland, Eric C.
    [J]. NEURO-ONCOLOGY, 2019, 21 (06) : 819 - 821
  • [9] Prognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes
    Darvishi, P.
    Batchala, P. P.
    Patrie, J. T.
    Poisson, L. M.
    Lopes, M. -B.
    Jain, R.
    Fadul, C. E.
    Schiff, D.
    Patel, S. H.
    [J]. AMERICAN JOURNAL OF NEURORADIOLOGY, 2020, 41 (05) : 815 - 821
  • [10] Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system
    Delev, Daniel
    Heiland, Dieter Henrik
    Franco, Pamela
    Reinacher, Peter
    Mader, Irina
    Staszewski, Ori
    Lassmann, Silke
    Grau, Stefan
    Schnell, Oliver
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2019, 141 (01) : 223 - 233